Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies
暂无分享,去创建一个
U. Germing | G. Kobbe | R. Fenk | R. Haas | K. Nachtkamp | A. Dienst | T. Schroeder | M. Kondakci | C. Rautenberg | E. Schuler | Sarah Boughoufala
[1] D. Wieczorek,et al. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] P. Vyas,et al. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia , 2018, Journal of internal medicine.
[3] M. Caligiuri,et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells , 2018, Nature Medicine.
[4] U. Germing,et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group , 2018, Annals of Hematology.
[5] A. Ganser,et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation , 2017, Haematologica.
[6] A. Vekhoff,et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia , 2017, Cancer.
[7] T. Berg,et al. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) , 2017, Leukemia.
[8] U. Germing,et al. Sorafenib and azacitidine as salvage therapy for relapse of FLT3‐ITD mutated AML after allo‐SCT , 2017, European journal of haematology.
[9] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[10] M. Patnaik,et al. Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML) , 2016 .
[11] Catherine J. Wu,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[12] J. Bourhis,et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia , 2016, Haematologica.
[13] Richard J. Buka,et al. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] N. Kröger,et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT , 2015, Bone Marrow Transplantation.
[15] N. Kröger,et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] P. Muranski,et al. Clinical and biological predictors of outcome following relapse of CML post-allo-SCT , 2015, Bone Marrow Transplantation.
[17] A. Lane,et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] K. Rezvani,et al. Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation , 2014, Bone marrow transplantation.
[19] N. Kröger,et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Kröger,et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation , 2013, Leukemia.
[21] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[22] J. Cigudosa,et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia , 2011, Haematologica.
[23] Krishna Komanduri,et al. Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.
[24] B. Sandmaier,et al. Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] M. Labopin,et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] G. Kobbe,et al. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. , 2007, Leukemia research.
[27] A. Barrett,et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.
[28] T. Braun,et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] H. Deeg,et al. Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[30] N. Kröger,et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.